ZYUS Life Sciences Corporation (ZYUS) - Total Assets
Based on the latest financial reports, ZYUS Life Sciences Corporation (ZYUS) holds total assets worth CA$10.85 Million CAD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
ZYUS Life Sciences Corporation - Total Assets Trend (2022–2024)
This chart illustrates how ZYUS Life Sciences Corporation's total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
ZYUS Life Sciences Corporation - Asset Composition Analysis
Current Asset Composition (December 2024)
ZYUS Life Sciences Corporation's total assets of CA$10.85 Million consist of 22.9% current assets and 77.1% non-current assets.
| Asset Category | Amount (CAD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CA$0.00 | 13.0% |
| Accounts Receivable | CA$52.00K | 0.4% |
| Inventory | CA$630.00K | 4.3% |
| Property, Plant & Equipment | CA$0.00 | 0.0% |
| Intangible Assets | CA$0.00 | 0.0% |
| Goodwill | CA$0.00 | 0.0% |
Asset Composition Trend (2022–2024)
This chart illustrates how ZYUS Life Sciences Corporation's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: ZYUS Life Sciences Corporation's current assets represent 22.9% of total assets in 2024, an increase from 9.7% in 2022.
- Cash Position: Cash and equivalents constituted 13.0% of total assets in 2024, up from 0.3% in 2022.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 63.0% in 2022.
- Asset Diversification: The largest asset category is inventory at 4.3% of total assets.
ZYUS Life Sciences Corporation Competitors by Total Assets
Key competitors of ZYUS Life Sciences Corporation based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Together Startup Network Ltd
TA:TGTR
|
Israel | ILA35.72 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩642.17 Billion |
|
Yuyu Pharma Inc
KO:000227
|
Korea | ₩202.42 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp Preferred
KO:000105
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
|
Ildong Holdings Co Ltd
KO:000230
|
Korea | ₩813.62 Billion |
ZYUS Life Sciences Corporation - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.10 | 0.24 | 0.46 |
| Quick Ratio | 0.07 | 0.11 | 0.18 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CA$-14.09 Million | CA$-10.82 Million | CA$-8.27 Million |
ZYUS Life Sciences Corporation - Advanced Valuation Insights
This section examines the relationship between ZYUS Life Sciences Corporation's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.41 |
| Latest Market Cap to Assets Ratio | 2.29 |
| Asset Growth Rate (YoY) | -64.8% |
| Total Assets | CA$14.67 Million |
| Market Capitalization | $33.60 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values ZYUS Life Sciences Corporation's assets at a significant premium (2.29x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: ZYUS Life Sciences Corporation's assets decreased by 64.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for ZYUS Life Sciences Corporation (2022–2024)
The table below shows the annual total assets of ZYUS Life Sciences Corporation from 2022 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CA$14.67 Million | -64.75% |
| 2023-12-31 | CA$41.63 Million | -35.67% |
| 2022-12-31 | CA$64.71 Million | -- |
About ZYUS Life Sciences Corporation
ZYUS Life Sciences Corporation manufactures and distributes cannabinoid-based therapeutics and product candidates in Canada, the United States, Australia, and the European Union. The company offers Trichomylin, a softgel capsules with fixed dose combination of cannabinoids formulated that is phase 2 clinical trial for the treatment of chronic pain in adults caused due to musculoskeletal injuries,… Read more